These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Felbamate in epilepsy therapy: evaluating the risks. Pellock JM Drug Saf; 1999 Sep; 21(3):225-39. PubMed ID: 10487399 [TBL] [Abstract][Full Text] [Related]
3. Evaluating the safety and efficacy of felbamate in the context of a black box warning: A single center experience. Shah YD; Singh K; Friedman D; Devinsky O; Kothare SV Epilepsy Behav; 2016 Mar; 56():50-3. PubMed ID: 26828692 [TBL] [Abstract][Full Text] [Related]
6. [The pharmacologic and clinical profile of the new anticonvulsant felbamate--an overview]. Steinhoff BJ Fortschr Neurol Psychiatr; 1994 Oct; 62(10):379-88. PubMed ID: 8001894 [TBL] [Abstract][Full Text] [Related]
7. Felbamate pharmacology and use in epilepsy. Burdette DE; Sackellares JC Clin Neuropharmacol; 1994 Oct; 17(5):389-402. PubMed ID: 9316688 [TBL] [Abstract][Full Text] [Related]
8. Increased seizure frequency associated with felbamate withdrawal in adults. Welty TE; Privitera M; Shukla R Arch Neurol; 1998 May; 55(5):641-5. PubMed ID: 9605720 [TBL] [Abstract][Full Text] [Related]
9. Felbamate in therapy-resistant epilepsy: an Italian experience. Felbamate Italian Study Group. Avanzini G; Canger R; Dalla Bernardina B; Vigevano F Epilepsy Res; 1996 Nov; 25(3):249-55. PubMed ID: 8956923 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Kaufman DW; Kelly JP; Anderson T; Harmon DC; Shapiro S Epilepsia; 1997 Dec; 38(12):1265-9. PubMed ID: 9578520 [TBL] [Abstract][Full Text] [Related]
11. The rise and fall of felbamate as a treatment for partial epilepsy--aplastic anemia and hepatic failure to blame? Thakkar K; Billa G; Rane J; Chudasama H; Goswami S; Shah R Expert Rev Neurother; 2015; 15(12):1373-5. PubMed ID: 26566191 [TBL] [Abstract][Full Text] [Related]
14. Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Palmer KJ; McTavish D Drugs; 1993 Jun; 45(6):1041-1065. PubMed ID: 7691493 [TBL] [Abstract][Full Text] [Related]
15. Felbamate as an add-on therapy for refractory epilepsy. Shi LL; Dong J; Ni H; Geng J; Wu T Cochrane Database Syst Rev; 2011 Jan; (1):CD008295. PubMed ID: 21249704 [TBL] [Abstract][Full Text] [Related]
16. [Felbamate: perspectives for new antiepileptic treatment]. Pérez-Miranda J; Aguirre J; Parrilla JL; Pérez Miranda M Rev Neurol; 1995; 23(124):1220-5. PubMed ID: 8556622 [TBL] [Abstract][Full Text] [Related]
17. Felbamate in an adult population with severe refractory epilepsy. Kearney H; Delanty N Ir Med J; 2009; 102(10):326-8. PubMed ID: 20108801 [TBL] [Abstract][Full Text] [Related]
18. Is there any future for felbamate treatment? Borowicz KK; Piskorska B; Kimber-Trojnar Z; Małek R; Sobieszek G; Czuczwar SJ Pol J Pharmacol; 2004; 56(3):289-94. PubMed ID: 15215558 [TBL] [Abstract][Full Text] [Related]